Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Asset disposition Quarterly results Inv. presentation
|
Outlook Therapeutics, Inc. (ONS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/06/2023 |
4
| Gangolli Julian S (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 370,282 options to buy
@ $0.24, valued at
$88.9k
|
|
10/05/2023 |
4
| Haller Julia A (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 210,225 options to buy
@ $0.24, valued at
$50.5k
|
|
10/05/2023 |
4
| Huang Andong (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 191,113 options to buy
@ $0.24, valued at
$45.9k
|
|
10/05/2023 |
4
| Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 210,225 options to buy
@ $0.24, valued at
$50.5k
|
|
10/05/2023 |
4
| Haddadin Yezan Munther (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 358,337 options to buy
@ $0.24, valued at
$86k
|
|
10/05/2023 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 372,671 options to buy
@ $0.24, valued at
$89.4k
|
|
10/05/2023 |
4
| HILZINGER KURT J (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 286,670 options to buy
@ $0.24, valued at
$68.8k
|
|
04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/31/2023 |
4
| Haddadin Yezan Munther (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
03/31/2023 |
4
| Haller Julia A (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
03/31/2023 |
4
| Huang Andong (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
03/31/2023 |
4
| Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
03/31/2023 |
4
| Gangolli Julian S (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
03/31/2023 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
03/31/2023 |
4
| THURMAN RANDY H (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
03/31/2023 |
4
| HILZINGER KURT J (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
01/24/2023 |
4
| Evanson Jeff (Chief Commercial Officer) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Sold 267,000 shares
@ $1.11, valued at
$296.4k
|
|
01/19/2023 |
4
| Evanson Jeff (Chief Commercial Officer) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Sold 27,162 shares
@ $1.31, valued at
$35.6k
Sold 33,738 shares
@ $1.25, valued at
$42.2k
Sold 103,255 shares
@ $1.22, valued at
$126k
|
|
12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/11/2022 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Bought 30,000 shares
@ $1.29, valued at
$38.7k
|
|
10/11/2022 |
4
| Haddadin Yezan Munther (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Bought 29,743 shares
@ $1.29, valued at
$38.4k
Bought 3,600 shares
@ $1.27, valued at
$4.6k
|
|
10/07/2022 |
4
| Haddadin Yezan Munther (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 71,998 options to buy
@ $1.25, valued at
$90k
|
|
10/07/2022 |
4
| HILZINGER KURT J (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 57,598 options to buy
@ $1.25, valued at
$72k
|
|
10/07/2022 |
4
| Gangolli Julian S (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 74,398 options to buy
@ $1.25, valued at
$93k
|
|
10/07/2022 |
4
| Haller Julia A (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 42,239 options to buy
@ $1.25, valued at
$52.8k
|
|
10/07/2022 |
4
| Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 42,239 options to buy
@ $1.25, valued at
$52.8k
|
|
10/07/2022 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 74,878 options to buy
@ $1.25, valued at
$93.6k
|
|
10/07/2022 |
4
| Huang Andong (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 38,399 options to buy
@ $1.25, valued at
$48k
|
|
10/05/2022 |
4
| HILZINGER KURT J (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Bought 95,541 shares
@ $1.29, valued at
$123.2k
Bought 15,662 shares
@ $1.23, valued at
$19.3k
|
|
10/03/2022 |
4
| HILZINGER KURT J (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Bought 13,800 shares
@ $1.19, valued at
$16.4k
Bought 33,199 shares
@ $1.26, valued at
$41.8k
Bought 41,798 shares
@ $1.25, valued at
$52.2k
|
|
08/15/2022 |
4
| Haller Julia A (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $1.15, valued at
$28.8k
|
|
|
|
|